Lenire Available with Treble Health Following Neuromod Partnership
- Neuromod will grow access and availability of Lenire through the Treble Health practice network in Philadelphia and Charlotte.
- Neuromod built its partnership with Treble Health on Lenire’s evidence base, which supports the device’s effectiveness and safety as a tinnitus treatment.
Philadelphia, Pennsylvania: Neuromod Devices Ltd. (Neuromod), the medical device company, has partnered with Treble Health. The partnership will expand the availability of Lenire in Philadelphia and Charlotte.
Tinnitus, commonly described as ringing, hissing, or buzzing in the ears, affects 25 million American adults. An estimated 185,000 adults live with tinnitus in Philadelphia, and 108,000 live with the condition in Charlotte.
Treble Health is a hearing health service specializing in the treatment of tinnitus. The service has treated 2,500+ patients since its establishment in 2020.
Recently, Treble Health expanded by establishing a physical network of practices in Charlotte, Philadelphia, and elsewhere in the USA. Physical practices complement its ongoing telehealth services.
This partnership ensures continued availability of Lenire to tinnitus patients via two Treble Health Network practices.
Evidence Driven Lenire Available with Treble Health
Lenire is a device that treats tinnitus with bimodal neuromodulation. Bimodal neuromodulation is the simultaneous stimulation of two nerves for therapeutic purposes.
Lenire plays audio tones via headphones while delivering mild energy pulses to the surface of the tongue to treat tinnitus. Patients with bothersome tinnitus typically use the device at home for two 30-minute sessions daily for approximately 12 weeks. A qualified audiologist guides treatment.
“The Lenire device has been an outstanding addition to our tinnitus treatment options as clinicians,” said Dr. Gail Brenner Au. D., tinnitus specialist at The Tinnitus Treatment Center of Philadelphia. “It gives us another intervention that has proven to benefit the vast majority of tinnitus patients. I am delighted to make it available to my patients as part of Treble Health.”
The partnership follows publication of positive treatment results of 140 real world U.S. patients in the American Journal of Audiology. 81.8% of patients with moderate or worse tinnitus demonstrated a clinically significant improvement after approximately 12-weeks of treatment with Lenire.2,3
“I’m delighted to make Lenire available to tinnitus patients at these two Treble Health in-person clinics. Since Lenire’s De Novo approval by the US FDA in 2023 we have seen evidence of great treatment outcomes for patients be peer-reviewed and published in respected scientific journals,” said Dr. Ben Thompson Au. D, founder of Treble Health. “These results make it clear that Lenire is an extremely strong treatment option for tinnitus patients.”
“Expanding the awareness and availability of Lenire to tinnitus patients in the USA and globally is a priority for Neuromod.” said Eric Timm, President, Global Commercial Operations & CEO, Neuromod USA Inc. “I’m delighted this partnership with Treble Health will give people living with tinnitus broader access to treatment with Lenire supported by guidance from expert clinicians.”
About Lenire®
Lenire® is the first non-invasive bimodal neuromodulation tinnitus treatment device. Large-scale clinical trials have shown the device can soothe and relieve tinnitus.
Bimodal neuromodulation stimulates nerves using two paired stimuli for therapeutic purposes. Neuromod Devices developed the tinnitus treatment device used in the study, known as Lenire.
It consists of wireless (Bluetooth®) headphones that deliver sequences of audio tones to both ears. This is combined with electrical stimulation pulses delivered to the surface of the tongue via 32 electrodes on a proprietary device trademarked as Tonguetip®. The device allows clinicians to configure settings that deliver treatment using different combinations of audio and electrical stimuli.
An easy-to-use handheld controller controls the timing, intensity, and delivery of the stimuli, and each participant receives training on how to use it before continuing treatment at home. Appropriately qualified healthcare professionals, such as audiologists or ENT surgeons, prescribe Lenire to patients with tinnitus after assessing their suitability, and patients can complete treatment at home between follow-up appointments with their clinician.
Lenire® has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional in Europe and has received a De Novo Approval Grant by the US FDA.
About Treble Health
Treble Health is a specialized hearing healthcare company focused on the evaluation and treatment of tinnitus. Founded by brothers Dr. Ben Thompson, AuD and Dr. Garrett Thompson, AuD, Treble Health was established to provide evidence-based, personalized care for individuals experiencing bothersome tinnitus.
Since 2020, Treble Health has treated more than 2,500 patients with tinnitus across the United States. Care is delivered by licensed audiologists with advanced training in tinnitus management, using a comprehensive clinical approach that may include tinnitus retraining therapy, sound therapy, cognitive behavioral strategies, and emerging treatment technologies.
Treble Health operates in the United States and provides care through a national telehealth platform as well as select in-person clinics. This hybrid care model allows patients to access specialized tinnitus expertise regardless of geographic location.
References and Notes
- https://www.nidcd.nih.gov/health/tinnitus
- Kasper, C et al. Bimodal Neuromodulation for Tinnitus in a Clinical Practice Setting: Clinically Significant Benefit for Patients with Moderate or Worse Symptoms, American Journal of Audiology, https://doi.org/10.1044/2025_AJA-25-00090 (2025)
- As measured by Tinnitus Handicap Inventory (THI).
